IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Regulatory Dossier : An Overview On CTD

Mohammed Farhan Makrani[*1], Dr. Anju Goyal[*2]

[*1,2] Department Of Quality Assurance Bhupal Noble's College Of Pharmacy, Udaipur, Rajasthan, India

Abstract

The Common Technical Document (CTD) was introduced to streamline the drug registration process over many countries, including the US, EU, and Japan, by standardizing the structure and content of regulatory dossiers. The aim of this strategy is to reduce the time, resources, and complexity required for pharmaceutical industries to secure marketing authorization in many nations. quality control, resource constraints, and language barriers continue to impact the execution of CTD, particularly in developing countries like India.

The Common Technical Document (CTD) was introduced to streamline the drug registration process over many countries, including the US, EU, and Japan, by standardizing the structure and content of regulatory dossiers. the aim of this strategy is to reduce the time, resources, and complexity required for pharmaceutical industries to secure marketing authorization in many nations. quality control, resource constraints, and language barriers continue to impact the execution of CTD, particularly in developing countries like India. administrative data, technical summaries, quality data, non-clinical study reports, and clinical study reports are all covered in the five modules in which CTD is divided. The adoption of the CTD facilitates faster regulatory reviews, improved communication between regulatory bodies, and the potential for electronic submissions. in spite these Benefit, challenges such as regulatory harmonization issues, the volume and difficulty of data, quality control, resource constraints, and language barriers continue to impact the implementation of CTD, particularly in developing countries like India. This article explores the structure, advantages, challenges, and limitations of the CTD, offering insights into its global impact and the hurdles faced by the pharmaceutical industry in regulatory submissions.

1 Introduction

The regulatory requirements for marketing authorisation of pharmaceutical products are the focus of the regulatory affairs (RA) field. In order to get good products to market and keep them there while limiting the sale of subpar and ineffective items, regulatory affairs specialists manage interactions between regulators (the government), the regulated [industry], and the market (consumers).(1)

The 1950s saw a number of tragedies, including the thalidomide, vaccination, and sulfanilamide elixir tragedies, which led to a significant increase in laws governing the efficacy, safety, and quality of pharmaceutical products. Stricter guidelines for Good Manufacturing Practices (GMPs) and Marketing Authorisation (MA) have also been the outcome of this. Making sure that all of the information about medications has been accurately provided to the patient, including labelling, is one of the regulatory authority's most important tasks. In addition to losing millions of dollars, a minor error in any regulatory activity could result in the product being recalled. (2)

Each nation has its own regulatory body, such as the Ministry of Health, Labour, and Welfare (MHLW) in Japan, the European Medicine Agency (EMA) in Europe, the Food and Drug Administration (FDA) in the United States, and the Central Drug Standard Control Organisation in India. The majority of regulatory bodies have their own application forms for requesting permission to commercialise a medication. This approval may be for an abridged NDA (ANDA) or a new drug application (NDA).(3)

In this manner, it is very difficult, particularly for the companies with worldwide approach to create one single regulatory approach for a Marketing Authorization Application (MAA) for a new drug on the basis of one dossier submitted at the same time to distinctive nations in the world. It is very important to know in detail and precisely the regulatory requirements in each concerned nation where a Registration Dossier should be submitted to build up a appropriate regulatory methodology before the submission in order to avoid any major difficulties. (4)

Pharmaceutical Dossier characterizes the collection of detailed documents containing data about a specific drug which require extensive information to be attached on the dossier for submission to Regulatory Authority for give of Regulatory Approval in any nation with which a Licensed Product must be enlisted or approved for the Manufacturing, Marketing, Utilize, Distribution or Sale of such Licensed Product in the Field. Commonly called as Marketing Authorization Application (MAA) for European Union and New Drug Application (NDA) for United Nation. (5)

Each application dossier contains detailed data on quality standards, pre-clinical, and clinical trials with respect to safety and efficacy. The volume of a dossier, therefore, may reach up to a few hundreds of thousands pages or even more. Its preparation includes lot of efforts in terms of time, money, and skilled people. Hence, if a pharmaceutical company has to market its drug in several nations, they have to file different applications in each nation which will lead to wastage of resources, time, and money. The data has to be arranged into different formats as per the requirement of individual regulatory agencies. For example, GAIYO format is required in Japan, while expert reports and tabulated summaries are required in Europe. Such overlapping and exclusive documentation may lead to exclusion of critical information in an application eventually postponing the approval process. Delay in approval of a drug translates into loss of time, money, and resources. In addition, it comes to the patients late and prolongs their suffering. (6)

The Common Technical Document (CTD) aimed to streamline the process of collecting applications for human medicine registration by making a uniform format for technical information that would permit for the

establishment of electronic submissions. In addition, if all regulatory authorities could utilize a single, standard document, it would speed up regulatory reviews, contact with the applicant, and the exchange of regulatory data. (7)

By characterizing the CTD as "a collection of data comprising scientific, manufacturing, clinical, and non-clinical data presented in a standardized format and with identical content," the FDA aimed to simplify the method of registering new pharmaceuticals in the US, EU, and Japan.(8)

2 Understanding the Common Technical Document (CTD)

A set of guidelines outlining the format and content of a new medicine application dossier that could be used in all three regions was created in 2000 by representatives of the European Medicines Agency (EMA), the FDA in the United States, and the Ministry of Health, Labour, and Welfare in Japan.

The International Conference on Harmonisation (ICH) oversaw the development of these recommendations, which are now a member of the ICH guidelines family. The CTD's goal was straightforward: it would give technical documentation a standard structure, which would greatly cut down on the time and resources required to gather applications for human pharmaceutical registration and make electronic submissions easier.

Additionally, the interchange of regulatory information between Regulatory Authorities would be streamlined, and a standard document with similar parts would improve regulatory evaluations and communication with the applicant. One There are now four ICH guidelines on the CTD (M4, M4Q, M4S, and M4E) as well as four question and answer publications. The first set of ICH CTD guidelines was published in 2002.

The CTD format was made required for NDAs in the EU and Japan in July 2003. It is also highly recommended for NDAs that are submitted to the FDA. Since the USA, Japan, and the EU adopted the CTD format, a number of other nations, notably Canada and Switzerland, have also done the same. With the eCTD being required for the centralised procedure in the EU since 2010, the paper CTD is now set to be superseded by its electronic cousin, the eCTD. (9)

3 General Principles

Just like any other document the CTD's information display should be clear and transparent. In the ICH M4 guideline manual on the organization of the CTD1 states that text and tables should be created with margins that allow the document to be printed on both A4 (EU and Japan) and 8.5 × 11" (USA) paper.

In order to avoid the binding approach concealing information, the left-hand margin should be sufficiently large. Fonts used in text and tables should be sufficiently large and readable, even after photocopying. For narrative writing, a 12-point Times New Roman font is recommended.

With the exception of particular literature references, where the current journal page numbering is deemed adequate, all documents included in the CTD should be numbered beginning on page 1. According to the

Uniform Requirements for Manuscripts Submitted to Biomedical Journals state that literature references must be included at the end of each module and that acronyms and abbreviations must be described the first time they are used. [10]

4 Common Technical Document Structure for India

In India, applications for pharmaceutical marketing authorisation are filed in the Common Technical Document (CTD) format. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are rigorously adhered to by the framework, which was developed specifically to speed up pharmaceutical registration procedures.

The five modules that make up the CTD have the following structure and content:

Module 1: Prescription and Administrative Data

- **Information Specific to the Nation:**
  - Application form for drug registration.
  - Indian-specific regulatory documentation and cover letters.
  - Material labelling and packaging (in regional languages or English, if necessary).
  - If appropriate, a Certificate of Pharmaceutical Product (CPP) in the format specified by the WHO.
  - Details on the manufacturing location or locations and licensing.

Module 2: Common Technical Document Summaries

2.1Clinical Summary: An overview of safety, efficacy, and clinical research data.
2.2 Non-clinical Summary: An overview of non-clinical studies conducted in the field of toxicology, pharmacology, and pharmacokinetics.
2.3 Quality Overall Summary (QOS): A summary of the substance's and drug product's quality information.

Module 3: Quality

- **Drug Substance (Active Pharmaceutical Ingredient):** Detailed information regarding the chemistry, manufacturing, and controls (CMC) of the active pharmaceutical ingredient (API).
- **Drug Product:** Information about the formulation, manufacturing process, quality control, and packaging of the finished drug product.
- **Stability Studies:** Details about the stability of the medication, such as its shelf life and storage needs.

Module 4: Non-clinical Study Reports

- **Pharmacology :** Main pharmacodynamic research and mechanisms of action.
- **Toxicology :** Details about toxicity investigations that are acute, sub-chronic, and chronic.
- **Safety Pharmacology :** Research into the medication's possible negative effects.
- **Pharmacokinetics :** The study of absorption, distribution, metabolism, and excretion (ADME) .

Module 5: Clinical Study Reports

- Clinical Trials Data: Detailed reports of clinical trials, including design, results, statistical analysis, and conclusions.
- Efficacy Data: Medical proof that backs up the treatment assertion.
- Safety Data: Details about risk management, pharmacovigilance, and side effects.[11][12][13][14][15][16]

5 Advantages Of CTD

I. The primary goal of establishing a standard submission format is to facilitate the evaluation of every application and prevent the omission of important information or analyses. Such information omissions may cause needless approval delays.

II. Having a standard format for technical material will make it easier to prepare electronic submissions and drastically cut down on the time and resources required to gather applications for human pharmaceutical registration.

III. A uniform document with common components will streamline regulatory reviews and correspondence with the applicant.

IV. It is anticipated that the adoption of CTD will drastically cut down on the time and resources required by industry to prepare applications for international registration.

V. In addition to improving the Indian standard, CTD will assist in giving the application procedure a correct framework. 6. Additionally, regulatory bodies will be able to exchange information more easily.[17]

6 Challenges and Limitations of the CTD

In order to standardise the submission procedure for pharmaceutical product regulatory approvals Including India and many countries have adopted the Common Technical Document (CTD) format. Even while the CTD format has numbers of benefits, using it might present a number of difficulties and restrictions, especially when it comes to regulatory filing in India and other developing markets.

I. Regulatory Harmonization Issues

- **Challenge :** Even though, the CTD format has been harmonized globally, not all nations have fully accept or follow to it. Especially in regions with weaker regulatory regimes, this may result in disparities between filings to various regulatory bodies.
- **Example :** Even though, India often complies with ICH principles, there can be still national requirements (such extra paperwork or language proficiency) that make the submission process more difficult

II. Complexity and Volume of Data

- **Challenge:** The CTD necessitates comprehensive documentation from five modules, including a wealth of information from manufacturing procedures, non-clinical research, and clinical trials. Large

and complex submission packages that need a many resources to create and assess may get up from this.

- **Limitation** : A small scale pharmaceutical businesses, particularly those who have minimum resources to compile an extensive submission, may find the required documentation too much to handle.

III. **Data Quality and Standardization**

- **Challenge:** It can be challenging to guarantee the accuracy and consistency of the information supplied in the various CTD parts. it may be more difficult for regulatory bodies to properly assess the information if there are variation in measurement, non clinical and clinical trial data are not standardized, and data presentation is different.
- **Limitation:** The approval process may be delayed or necessitate further explanations due to inconsistent data presentation and quality control problems.

IV. **Lack of Skilled Resources**

- **Challenge:** High levels of technical proficiency in a variety of fields, such as pharmacology, toxicology, clinical research, and regulatory affairs, are required for the CTD format. Finding or training experts with the necessary abilities to gather and handle CTD submissions may be challenging for businesses, especially smaller ones.
- **Limitation:** Inadequately prepared submissions, mistakes, and approval delays may result from a lack of qualified personnel.

V. **Regulatory Bottlenecks and Delays**

- **Challenge:** In certain nations, such as India, backlogs, a shortage of personnel, and ineffective CTD submission processing can cause the regulatory process to move slowly.
- **Limitation:** Pharmaceutical companies' ability to compete may be impacted by these delays, which could lengthen the time it takes for new medications to reach the market.

VI. **Language Barriers and Translation Issues**

- **Challenge:** Many regulatory bodies mandate that certain sections be translated or that submissions be made in the local language. Multinational pharmaceutical corporations face difficulties as a result, particularly in nations like India where English and regional languages coexist.
- **Limitation:** Delays and extra expenses may result from the requirement for translations and making sure that regulatory phrases are correctly communicated.

VII. Cost of Preparing and Submitting CTD

- **Challenge:** The process of preparing a CTD submission requires significant investment in resources, both human and technical. For small and medium-sized pharmaceutical companies, the costs associated with complying with the CTD format can be prohibitive.
- **Limitation:** High costs for document preparation, legal and regulatory fees, and clinical trials can be a barrier to market entry, especially for smaller players.

VIII. Differences in Data Requirements

- **Challenge:** Despite the fact that the CTD format is globally standardised, certain regulatory bodies can need more information or have different interpretations of the data that is already available. The approval procedure may be delayed as a result of the requirement for more paperwork or changes to the application.
- **Limitation**: Global pharmaceutical development and approval processes are made more complex by regulatory authorities' inconsistencies. [18][19][20][21][22]

7 Conclusion

The regulatory affairs field plays a important role in ensuring that pharmaceutical products are safe, effective, and of high quality. Regulatory bodies have underlined the importance of strict standards and frameworks for marketing authorization due to the increasing worldwide and difficulty of the pharmaceutical sector business.

However, the execution of the CTD is not without its challenges. Regulatory harmonization issues, especially in regions with poor regulatory frameworks, can result in incompatibility in how applications are submitted and evaluated. The difficulty and volume of information required for CTD submissions can overwhelm smaller pharmaceutical companies, leading to delays or errors in the approval process.

Furthermore, to make sure high-quality, standardized data and reduce language barriers further intricate the regulatory process, mainly in countries like India where people speak multiple languages.

In spite of these issues, the CTD framework offers several merits, including decreasing the time and resources needed for drug registration, improving communication between regulatory bodies and applicants, and enhancing the overall quality of submissions. The continued evolution of electronic submissions (eCTD) further supports these attempt by improving efficiency and decreasing manual effort.

Ultimately, while the CTD framework has revolutionized global regulatory submissions, continuous advances and structure of national regulations with international standards are important to lessen the difficulties faced by pharmaceutical industries and ensure a more efficient drug approval process worldwide.

Regulatory authorities must work collectivly to face these difficulties, ensuring that the system remains flexible and responsive to the ever-evolving situation of global pharmaceutical markets.

8 References

1. Huma T., Peng Z., Introduction to Regulatory Affairs and Different Regulatory Bodies for Pharmaceutical Products and Impact of Digitalization on Regulatory Affairs, Scientific Research Publishing Inc., Pharmacology & Pharmacy, 2023, 14, 463-77.
2. Lale1 S., Kendre A., Gandhi M., and Dani S., Role Of Drug Regulatory Affairs In Pharma Industry, World Journal of Pharmaceutical Research, Volume 4, Issue 6, 615-625.
3. Gupta A. and Rai S., Regulatory Dossier Submission In India, Asian Journal of Pharmaceutical Research and Development, Vol. 3 (4) July – August. 2015:1-8.
4. Godiyal S., Regulatory requirements for preparation of Dossier for registration of Pharmaceutical products in ACTD & CTD format, International Journal of Drug Regulatory Affairs. 2019; 7(2):51-61.
5. Garg V., Chopra S., Singh S. K., Gulati M., Kumar B. and Mittal N., A comparative study of common technical document in different regulated market, Journal of Pharmacy Research, Vol 11, Issue 8, 2017, 1045-24.
6. Saraswat R., Raikwar A. and Panda S., Streamlining Regulatory Documentation: Exploring The Common Technical Document (CTD) And Electronic Submission, With Emphasis On M Series According To Ich Guidelines, Asian J Pharm Clin Res, Vol 17, Issue 10, 2024, 1-7.
7. Jordon D., An overview of the Common Technical Document (CTD) regulatory dossier, Medical Writing 2014, VOL. 23 NO. 2, 1-105.
8. Organisation Of The Common Technical Document For The Registration Of Pharmaceuticals For Human Use M4, International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use Ich Harmonised Guideline, 2017, 1-22
9. Organisation Of The Common Technical Document For The Registration Of Pharmaceuticals For Human Use M4, International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use, June 2016,1-22.
10. Jordan D., An overview of the Common Technical Document (CTD) regulatory dossier, The European Medical Writers Association 2014, VOL. 23;2, 101-5.
11. Government of India. (1940). Drugs and Cosmetics Act, 1940
12. Government of India. (1945). Drugs and Cosmetics Rules, 1945.
13. World Health Organization. (2019). WHO CTD Guidelines
14. Government of India. (1945). Schedule M - Good Manufacturing Practices.
15. Government of India. (1945). Schedule Y - Guidelines for Clinical Trials.
16. International Council for Harmonisation. (2016). ICH E6 Good Clinical Practice (GCP).
17. Mahaparale S. P. and Desai B. R., Role And Overview Of Drug Regulatory Affairs In Pharmaceutical Industry With Implementation Of CTD and ECTD, World Journal of Pharmaceutical Research, Vol 7, Issue 7, 2018., 201-15.

18. CDSCO Guidelines on Drug Registration
19. ICH Guidelines (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use).
20. CDSCO Drug Approval Process.
21. Indian Pharmacopoeia
22. WHO Good Manufacturing Practice (GMP) Guidelines.